RNA sequencing of pre-treatment primary cervical cancer. RNA sequencing of pre-treatment primary cervical cancer

Investigate the transcriptomic differences between HPV-positive and HPV-negative primary cervical tumors. Overall design: Whole transcriptome sequencing was performed on 68 pre-treatment, primary cervical cancer samples from cervical cancer patients treated at the Washington University School of Medicine. A minimum of 0.5µg of RNA with RIN > 7 was extracted for library preparation. Sequencing was performed using Illumina HiSeq 3000, 1x50nt, ~40 million reads per sample), and aligned to GRCh38 using STAR 2.7.0f.

本研究旨在探究人乳头瘤病毒（HPV）阳性与HPV阴性原发性宫颈肿瘤之间的转录组学差异。
实验设计概况：本研究针对华盛顿大学医学院（Washington University School of Medicine）收治的68例治疗前原发性宫颈癌样本开展全转录组测序。所有样本均提取总量不低于0.5μg的RNA，且RNA完整性指数（RNA Integrity Number，RIN）>7，用于文库构建。测序采用Illumina HiSeq 3000平台，测序模式为1×50nt单端测序，每个样本产出约4000万条读段；随后使用STAR 2.7.0f工具将测序读段比对至GRCh38参考基因组。